Relevant bibliographies by topics / Anti-coagulation therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Anti-coagulation therapy'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-coagulation therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti-coagulation therapy"

1

SOEJIMA, Hirofumi, Koichi KAIKITA, Seiji HOKIMOTO, Kenichi TSUJITA, and Hisao OGAWA. "Anti-coagulation and anti-platelet therapy for heart disease." Japanese Journal of Thrombosis and Hemostasis 23, no. 1 (2012): 25–32. http://dx.doi.org/10.2491/jjsth.23.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Miyazaki, Yusuke, Kazuhiro Sase, Koji Hasegawa, and Tatsuya Morimoto. "VTE and anti-coagulation therapy in cancer patients." European Heart Journal - Cardiovascular Pharmacotherapy 5, no. 4 (2019): 189–91. http://dx.doi.org/10.1093/ehjcvp/pvz027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Eguchi, Y. "EFFICACY OF ANTI-COAGULATION AND ANTI-INFLAMATORY THERAPY FOR SEVERE SEPSIS." Journal of Thrombosis and Haemostasis 5 (July 2007): P—M—223—P—M—223. http://dx.doi.org/10.1111/j.1538-7836.2007.tb01158.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nasreen, Noor Suhail Ahmed Almani Shafaq Nazia Muhammad Iqbal Shah* Aatir H. Rajput Muhammad Muneeb Syed Jehangir and Shahrukh Shaikh. "CROSS-SECTIONAL ANALYSIS OF DANGERS INHERENT WITH PRE AND POST PARTUM USE OF ANTICOAGULATION THERAPY." Indo American Journal of Pharmaceutical Sciences 04, no. 06 (2017): 1422–25. https://doi.org/10.5281/zenodo.817584.

Full text
Abstract:
Background:The rate of thrombotic mal-events is three-fold to five-fold greater during pre-partum and post-partum phases than at any other time in a women’s life and thus many women receive anticoagulant therapy during pregnancy and puerperium, despite evidence suggesting that this therapy may pose grave danger to the well-being of the fetus and the mother. Objective: This research hopes to highlight the dangers inherent (to the mother and fetus) with the pre-partum and post-partum use of anti-coagulation therapy. Methodology This retrospective analysis is built upon the primary data, availabl
APA, Harvard, Vancouver, ISO, and other styles
5

Ikura, Yoshihiro. "Changing common sense: Anti-platelet/coagulation therapy against cirrhosis." World Journal of Hepatology 7, no. 13 (2015): 1730. http://dx.doi.org/10.4254/wjh.v7.i13.1730.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Harky, Amer, Perry Maskell, and Mika Burgess. "Anti-platelet and anti-coagulant therapy in peripheral arterial disease prior to surgical intervention." Vascular 27, no. 3 (2018): 299–311. http://dx.doi.org/10.1177/1708538118818622.

Full text
Abstract:
Objective Peripheral artery disease is a major clinical co-morbidity that can significantly affect quality of life, especially in the presence of diabetes mellitus and older age. The focus of this literature review is on medical management, through anti-platelet and anti-coagulation, of peripheral artery disease prior to undergoing surgical or endovascular management. Method Extensive electronic literature search performed in four major databases (PubMed, SCOPUD, Embase and Ovid) to identify the published randomized and non-randomized studies that compared and discussed the management of perip
APA, Harvard, Vancouver, ISO, and other styles
7

Katargina, L. A., and E. N. Demchenko. "New opportunities in management of patients with retinopathy prematurity (literature review and analysis of own data)." Russian Ophthalmological Journal 13, no. 4 (2020): 70–74. http://dx.doi.org/10.21516/2072-0076-2020-13-4-70-74.

Full text
Abstract:
Insufficient effectiveness of laser coagulation of the avascular retinal areas in retinopathy of prematurity (ROP) plus-disease in zone I and aggressive posterior retinopathy of prematurity (APROP) requires new treatment approaches, based on the regulation of retinal angiogenesis and anti-VEGF drugs use. The BEAT-RAP study, which was the first major randomized study of anti-VEGF therapy in ROP, revealed a higher effectiveness of bevacizumab compared to retinal laser coagulation in stage 3 plus-disease of zone I. A prospective randomized trial, RAINBOW, demonstrated the effectiveness of ranibiz
APA, Harvard, Vancouver, ISO, and other styles
8

Valaitienė, Julija. "IMPACT OF CONTACT SYSTEM ON CARDIOVASCULAR DISEASES." Health Sciences 34, no. 3 (2024): 164–68. http://dx.doi.org/10.35988/sm-hs.2024.126.

Full text
Abstract:
Contact and intrinsic coagulation pathway components are involved in pathological thrombus formation. In addi­tion to coagulation, contact system activation is involved in anti/profibrinolytic and inflammatory processes that can contribute to the atherosclerotic and thrombotic en­vironment, leading to cardiovascular diseases. This lite­rature review concerns the role of the contact system on cardiovascular diseases and accentuates the potential of coagulation factors FXII (FXII) and FXI (FXI) as targets for antithrombotic therapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Wallace, John L. "Novel Targets for Anti-Inflammatory Therapy in Inflammatory Bowel Disease." Canadian Journal of Gastroenterology 8, no. 6 (1994): 373–78. http://dx.doi.org/10.1155/1994/765272.

Full text
Abstract:
Until the cause(s) of inflammatory bowel disease are identified, improvements in therapy will likely come from improved anti-inflammatory therapy or improved drug delivery systems. There are many potential targets for anti-inflammatory therapy, including the synthesis of specific inflammatory mediators. This review focuses on the potential for developing therapy aimed at three targets: nerves and neuropeptides; coagulation and thrombosis; and adhesion molecules. In each case, evidence is presented from clinical and/or experimental studies that supports the hypothesis that these are rational ta
APA, Harvard, Vancouver, ISO, and other styles
10

Lim, Cheryl XQ, Priscella Shirley Chia, and Eng Soo Yap. "Asian Experience of Treating Venous Thromboembolism in Patients with Acute Leukaemia." Blood 134, Supplement_1 (2019): 1161. http://dx.doi.org/10.1182/blood-2019-130041.

Full text
Abstract:
Background Cancer is a known risk factor for venous thromboembolic (VTE) events. Thromboembolism occurs frequently during acute leukemia and the reported incidence of VTE in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are 5% and 6% respectively. However, majority of studies are conducted in Western population and data on VTE events in Asians with acute leukemia is scarce with only 1 published study. Objectives We aim to retrospectively evaluate the risk of thrombosis in Asian patients with acute leukemia and share our experience treating them. Patients and Methods This
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anti-coagulation therapy"

1

Tseng, Shen Jui, and 曾紳睿. "In vitro thrombolytic and anti-coagulation synergy therapy of multifunctional magnetic nanodrug delivery system." Thesis, 2013. http://ndltd.ncl.edu.tw/handle/58392549143342138645.

Full text
Abstract:
碩士<br>長庚大學<br>化工與材料工程學系<br>101<br>In this study, we designed a magnetic nano-carrier (MNC) for drug delivering, which composed of conductive polymer SPAnH as a shell and Fe3O4 as a core to form shell-core structure MNC and exerted superparamagnetic particularity. The average diameter of MNCs was 22 nm. The –COOH groups of MNCs was up to 15.5 × 10-5 mmol per mg of MNCs and the bio-conjugation of urokinase by covalent bonding on MNCs (UK/MNCs) was up to 55,470 U per mg of MNCs. Due to acid doping properties of SPAnH, acid-based enoxaparin was easily and quickly bound on UK/MNCs to form a novel n
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Anti-coagulation therapy"

1

Dawson, Dana, and Keith Fox. Anti-Platelet and Anti-Thrombotic Therapy Post-AMI. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0004.

Full text
Abstract:
• Acute coronary syndromes (ACS) encompass a spectrum of presentations which include unstable angina, non-ST-elevation myocardial infarction (NSTEMI or NSTE-ACS), and ST-elevation myocardial infarction (STEMI or STE-ACS)• Anti-platelet and anti-thrombotic agents are administered as ancillary therapy to myocardial reperfusion in patients presenting with an acute coronary syndrome, to maintain the patency of the infarct-related coronary artery• More specific and potent inhibitors of platelet activation and of the coagulation cascade are emerging with the aim being to further improve clinical out
APA, Harvard, Vancouver, ISO, and other styles
2

Stanworth, Simon, and Stuart McKechnie. Pathophysiology of disordered coagulation. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0269.

Full text
Abstract:
Imbalances in the regulation of haemostasis may manifest as bleeding (depletion of pro-coagulant factors) or thrombosis (deficiency of anti-coagulants). Disordered haemostasis is common in critically-ill patients and may result from infection, trauma, haemorrhage, inflammation, organ dysfunction (notably renal and liver dysfunction), or drug therapy. Complex patterns of coagulopathy where both bleeding and prothrombotic tendencies co-exist are well recognized in critical illness. The limitations of standard laboratory coagulation tests to predict bleeding risk, including activated partial thro
APA, Harvard, Vancouver, ISO, and other styles
3

Khamashta, Munther A., Graham R. V. Hughes, and Guillermo Ruiz-Irastorza. Anti-phospholipid antibody syndrome. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0120.

Full text
Abstract:
The anti-phospholipid syndrome (APS) described almost 30 years ago, is now recognized as a major cause of deep vein thrombosis, stroke, and heart attacks in young people (&lt;45 years of age). It is also the commonest treatable cause of recurrent miscarriages and a major cause of late fetal death. Other clinical manifestations are cardiac valvular disease, livedo reticularis, renal thrombotic microangiopathy, thrombocytopenia, haemolytic anaemia, epilepsy, and cognitive impairment. The presence of anti-phospholipid antibodies (aPL) has been closely related to the development of thrombosis and
APA, Harvard, Vancouver, ISO, and other styles
4

Khamashta, Munther A., Graham R. V. Hughes, and Guillermo Ruiz-Irastorza. Anti-phospholipid antibody syndrome. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199642489.003.0120_update_001.

Full text
Abstract:
The anti-phospholipid syndrome (APS) described almost 30 years ago, is now recognized as a major cause of deep vein thrombosis, stroke, and heart attacks in young people (&lt;45 years of age). It is also the commonest treatable cause of recurrent miscarriages and a major cause of late fetal death. Other clinical manifestations are cardiac valvular disease, livedo reticularis, renal thrombotic microangiopathy, thrombocytopenia, haemolytic anaemia, epilepsy, and cognitive impairment. The presence of anti-phospholipid antibodies (aPL) has been closely related to the development of thrombosis and
APA, Harvard, Vancouver, ISO, and other styles
5

Alchi, Bassam, and David Jayne. The patient with antiphospholipid syndrome with or without lupus. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0164.

Full text
Abstract:
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent arterial or venous thrombosis and/or pregnancy loss, accompanied by laboratory evidence of antiphospholipid antibodies (aPL), namely anticardiolipin antibodies (aCL), lupus anticoagulant (LA), and antibodies directed against beta-2 glycoprotein 1 (β‎‎‎2GP1). APS may occur as a ‘primary’ form, ‘antiphospholipid syndrome,’ without any known systemic disease or may occur in the context of systemic lupus erythematosus (SLE), ‘SLE-related APS’. APS may affect any organ system and displays a broad spectrum of thromb
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Anti-coagulation therapy"

1

Zhou, Wei, Zhaoyang Guo, Kangkang Wang, Haibo Zhang, and Xuemao Guan. "Influence of Anti-Mud Agent on the Performance of Gangue Backfilling Paste." In Lecture Notes in Civil Engineering. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-2532-2_29.

Full text
Abstract:
AbstractAnti-mud agents could improve the efficiency of the action of water reducers in concrete by preferentially. The anti-mud agent was preferentially adsorbed on the clay surface, which reduces the ineffective adsorption of the water reducing agent to the paste, thereby improving the water reduction efficiency. However, its application in high-sediment content coal gangue gypsum backfill materials had not been reported. In this paper, The competitive adsorption mechanism echanism of anti-mud agent was first described. Tested its competitive adsorption with water reducer molecules on the su
APA, Harvard, Vancouver, ISO, and other styles
2

Becker, Richard C., and Frederick A. Spencer. "Thrombin-Directed Therapy." In Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0020.

Full text
Abstract:
Anticoagulant therapy in general is designed to prevent either the generation or activity of thrombin; however, a cell-based model of coagulation provides a physiologic view of individual phases of the process, allowing more specific targets for attenuating the initiation, priming, or propagation of thrombus formation. Future categorization schemes will consider individual coagulation factors, individual sites on a given coagulation factor, and specific phases of coagulation to better identify an agent’s biochemical and physiologic activity. Unfractionated heparin (UFH) is a heterogeneous, neg
APA, Harvard, Vancouver, ISO, and other styles
3

Petrovic, Stanko, Slobodan Obradovic, Marijana Petrovic, and Nemanja Rancic. "Platelets in Ulcerative Colitis: From Pathophysiology to Therapy." In Ulcerative Colitis [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.102041.

Full text
Abstract:
Based on the role of platelets in inflammation and hemostasis it has been assumed that antiplatelet therapy could be beneficial for patients suffering from ulcerative colitis. Platelets present a link between inflammation and coagulation. They have more than 300 active mediators stored in their granules. Upon activation, platelet degranulate and release a lot of microparticles and mediators and interact with other immune and non-immune cells thereby amplifying inflammation. The most important parameters of platelet activation are P-selectin and CD40 ligand expressed on their surface upon activ
APA, Harvard, Vancouver, ISO, and other styles
4

Khamashta, Munther A., Graham R. V. Hughes, and Guillermo Ruiz-Irastorza. "Anti-phospholipid antibody syndrome." In Oxford Textbook of Rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0120_update_002.

Full text
Abstract:
The anti-phospholipid syndrome (APS) described almost 30 years ago, is now recognized as a major cause of deep vein thrombosis, stroke, and heart attacks in young people (&lt;45 years of age). It is also the commonest treatable cause of recurrent miscarriages and a major cause of late fetal death. Other clinical manifestations are cardiac valvular disease, livedo reticularis, renal thrombotic microangiopathy, thrombocytopenia, haemolytic anaemia, epilepsy, and cognitive impairment. The presence of anti-phospholipid antibodies (aPL) has been closely related to the development of thrombosis and
APA, Harvard, Vancouver, ISO, and other styles
5

Arias-Herrera, Santiago, Rebeca Sánchez-Martos, and Lourdes Alfaro-Ochoa. "Introduction to Diode Laser Therapies in Dentistry." In Recent Advances and Future Perspectives in Periodontology [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.1004531.

Full text
Abstract:
Actually, there are different types of lasers that can be used in dentistry, being the diode laser one of the most popular. The therapies in which diode laser is used are photothermic therapy, which is subdivided into low- and high-intensity photothermal therapy and photodynamic therapy. Photothermic therapy is based on an increase in local temperature, allowing the incision, excision, ablation, and vaporisation of the tissues, as well as haemostasis and coagulation of lesions. It also produces bacterial decontamination through thermal photo disinfection. Low-intensity photothermic therapy als
APA, Harvard, Vancouver, ISO, and other styles
6

Vesce, Fortunato. "From Pregnancy Loss to COVID 19 Cytokine Storm: A Matter of Inflammation and Coagulation." In Interleukins - The Immune and Non-Immune Systems’ Related Cytokines. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96884.

Full text
Abstract:
Large scientific evidence achieved during the second half of the past century points to a leading role of inflammation in the pathogenic mechanism of the main pregnancy complications, such as abortion, pregnancy loss, premature delivery, infection, fetal encephalopathy, enterocolitis, pulmonary hyaline membrane diseases and death. Thinking about pregnancy inflammation, one must refer today to the umbalance of the normal mediators of organic functions: cytokins, peptides, nucleosides, prostanoids. Indeed, according to the order and quantity of their release, they are involved either in physiolo
APA, Harvard, Vancouver, ISO, and other styles
7

Shaikh, Nissar, Narges Quyyum, Arshad Chanda, et al. "Pulmonary Embolism in COVID-19 Patients: Facts and Figures." In Pulmonary Embolism [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.99942.

Full text
Abstract:
COVID-19 infection affects many systems in the body including the coagulation mechanisms. Imbalance between pro-coagulant and anticoagulant activities causes a roughly nine times higher risk for pulmonary embolism (PE) in COVID-19 patients. The reported incidence of PE in COVID-19 patients ranges from 3 to 26%. There is an increased risk of PE in hospitalized patients with lower mobility and patients requiring intensive care therapy. Obesity, atrial fibrillation, raised pro-inflammatory markers, and convalescent plasma therapy increases the risk of PE in COVID-19 patients. Endothelial injury i
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anti-coagulation therapy"

1

Redaelli, R., F. Baudo, B. Busnach, et al. "LUPUS ANTICOAGULANT (LA) COEXISTENT WITH TRANSIENT PROTHROMBIN (FII) INHIBITOR: FTI DEFICIENCY DUE TO CLEARANCE OF THE B/MUNOCOMPLEX." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644240.

Full text
Abstract:
23 y.o. man with acute nephritis and bleeding (epistaxis, ecchymosis) at presen-taticn. Family and personal past history negative for bleeding. Laboratory data consistent with SLE. Coagulation tests: FT Ratio (R) 1.8, aPTT R 2.4, FII:C &lt;1%, FIIR:Ag 996, other coagulation factors normal. Tissue thromboplastin inhibition test (TTIT) R 2.8, congenital FII deficiency (696) R 1.6.1. FII survival time (Fll-ccncentrate infusion - 60 U/kg) t1/2: 9 hours.2. FII neutralizing activity (FTI:C normal plasma (NP) + buffer 5996; NP + patient plasna {PtP) 5096): absent.3. Irmunoccrplex formaticn4. FII inhi
APA, Harvard, Vancouver, ISO, and other styles
2

Mukhlova Montiel, M., and H. Bussey. "RESPONSE OF PROTEIN C AND PROTEIN S INHIBITORS IN LONG-TERM ORAL ANTICOAGULANT THERAPY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643877.

Full text
Abstract:
Protein C (PC) and its coenzyme Protein S (PS) are physiologic inhibitors of activated factors Va and Villa. Deficiency of either one of these inhibitors has been associated with venous thrombosis. Their activity is dependent on vitamin K for hepatic gamma carboxylation and it is depressed during oral anticoagulant therapy. Because rebound thrombosis complicates cessation of anticoagulant therapy, we investigated the response of PC and PS during long term oral anti coagulation. The study encompassed 30 patients ranging between 26 and 76 years of age, who have received therapeutic doses of coum
APA, Harvard, Vancouver, ISO, and other styles
3

Mirshahi, Mc, J. Soria, C. Soria, et al. "DISSOCIATION BETWEEN DDE LEVEL AND RECANALIZATION IN PATIENTS UNDERGOING THROMBOLYTIC THERAPY FOR MYOCARDIAL INFARCTION. A POSSIBLE EXPLANATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642983.

Full text
Abstract:
The aim of this work was to determine whether plasma fibrin degradation products (FbDP) level may be used as a marker of recanalization in patients undergoing thrombolytic therapy for myocardial infarction. Samples were collected in patients treated by a 90 minutes infusion of 60 mg recombinant tissue type plasminogen activator (rtpA). Plasma FbDP (DDE complexes) were specifically and reliably determined by Elisa using a personal monoclonal antibody. Additional identification of FbDP and fibrinogen derived fragment D was performed by SDS PAGE followed by their detection using an anti D neo mon
APA, Harvard, Vancouver, ISO, and other styles
4

Seifried, E., and P. Tanswell. "IN VITRO EFFECTS OF RECOMBINANT TISSUE TYPE PLASMINOGEN ACTIVATOR ON FIBRINOLYTIC AND COAGULATION PARAMETERS AND ITS PREVENTION BY SPECIFIC ANTIBODY, D-PHE-PRO-ARG-CTUCl AND APROTININ." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643119.

Full text
Abstract:
Monitoring of systemic effects during rt-PA therapy has shown of depletion of fibrinogen-antiplasmin, plasminogen and other hemostatic factors. Because in vitro activation of plasminogen may occur between blood collection and freezing and thawing before assaying we analysed the influence of 0,0.2, 2.0 and 10.0,ug rt-PA/ml citrate blood (final conc.) on hemostatic and fibrinolytic parameters and its inhibition by 3 different inhibitors. Addition of rt-PA to citrated whole blood without an inhibitor induced a concentration-dependent depletion of Fbg, Plgα2-Apl,α2-M, C1 - I, α2-Atrp, a loss of ac
APA, Harvard, Vancouver, ISO, and other styles
5

Zimmermann, R., A. Horn, C. Bode, et al. "COAGULATION CHANGES UNDER THREE DIFFERENT DOSAGE REGIMENS OF SINGLE-CHAIN UROKINASE TYPE PLASMINOGEN ACTIVATOR." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643036.

Full text
Abstract:
Therapy with streptokinase and urokinase induce effective thrombolysis but may be complicated by hemorrhagic side effects. In order to minimize these complications single-chain urokinase-type plasminogen activator (scu-PA) was given in patients with acute transmural myocardial infarction at three different dosage regimens consecutively in combination with heparin. In a first group four patients received 15 mg, thirteen 48 mg (group II) and five 72 mg (group III) of scu-PA intravenously. In 22 cases detailed clotting analyses could be performed. Results: The coagulation analysis demonstrated a
APA, Harvard, Vancouver, ISO, and other styles
6

Perry, D. J., and F. G. H. Hill. "HUMAN AND PORCINE FVIII INHIBITOR RESPONSE FOLLOWING INFUSION OF HUMAN FVIII CONCENTRATE - MEASUREMENT USING AN AGAROSE GEL SYSTEM." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644056.

Full text
Abstract:
Conventional methods for determining inhibitor levels in haemophiliacs are time consuming and labour intensive. The agarose gel technique of Jorquera et al. (1) has been modified and standardized to measure human and porcine inhibitors to VIII:C.26 samples from 12 haemophiliacs with inhibitors were analysed and in all cases antibody to human and porcine VIII:C was detected.Six haemophiliac patients with 'high responder-type' inhibitors were studied using stored plasma and the rise in antibody titres to both human and porcine VIII:C was determined sequentially during treatment with human FVIII
APA, Harvard, Vancouver, ISO, and other styles
7

Lavenne-Pardonge, E., C. Col-De Beys, R. Dion, R. Ponlot, and M. Moriau. "EFFECT OF ANTIAGGREGANT ON OCCLUSION OF SAPHENOUS GRAFT CORONARY BYPASS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644823.

Full text
Abstract:
Double blind study on 49 patients, 24receiving aspirine-dipyri-damole, 25 a placebo. In both groups 20 patients were followed during one year. The two groupsdid not differ according to age, sex and number of coronary bypass. In all the patients, Calparin (3 x 5000 U/day) was injected subcutanously the day before andthe 7 days after surgery. In the first group dipyridamole (25 mg/ kg) was injected during the same period. The second group received a placebo IV injection. Thereafter long acting dipyridamole (400 mg/day) and aspirin (200 mg/day) were given orally in the first group, placebo in the
APA, Harvard, Vancouver, ISO, and other styles
8

Forleo, Marcio H., Brennan M. Johnson, and Lakshmi P. Dasi. "Effect of Blood Pressure on Closing Dynamics of Bileaflet Mechanical Heart Valves." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80736.

Full text
Abstract:
Implantation of a bileaflet mechanical heart valve (BMHV) continues to be associated with a risk of thromboembolic complications despite anti-coagulation therapy1. This has been attributed to the structurally rigid design of the leaflets and valve mechanics combined with an intricate hinge mechanism for the rigid leaflets. The lack of a built in compliance within the valve mechanics presumably leads to sharp stress gradients within the flow as well as a violent closure of the valve often associated with the audible impact of the leaflets to the housing, and a potential for momentary cavitation
APA, Harvard, Vancouver, ISO, and other styles
9

Pengo, V., M. J. Heine, P. Thiagarajan, and s. s. Shapiro. "A GENERAL MECHANISM FOR LUPUS ANTICOAGULANTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643660.

Full text
Abstract:
Although- a number of observations have implied that lupus anticoagulants have immunologic specificity towards anionic. phospholipids, thereby prolonging phospholipid-dependent coagulation tests, this assumption has been directly demonstrated in only one patient with a monoclonal IgM paraprotein. We have tested the generality of this hypothesis directly by isolating five IgG lupus anticoagulants from patients with lupus-like syndromes and/or thrombosis. IgG lupus anticoagulant fractions were isolated free of other plasma proteins and free of contaminating phospholipid by adsorption to and elut
APA, Harvard, Vancouver, ISO, and other styles
10

Pieters, J., G. willems, H. C. Hemker, and T. Lindout. "EFFECT OF ANTITHROMBIN III AND HEPARIN ON FACTOR X ACTIVATION BY FACTOR IXa." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643767.

Full text
Abstract:
The heparin-catalyzed inactivation of activated coagulation factors by antithrombin III (AT III) has mostly been studied for isolated serine proteases. However, we decided to study the action of heparin and AT III under more physiological conditions, i.e. during the activation of factor X by factor IXa in the presence of phospholipid and calcium. Thereby we made use of a mathematical model which describes the generation of factor Xa by factor IXa, phospholipid and calcium in the presence of AT III and heparin. Fitting the experimental factor Xa generation curve to a set of equations gave the p
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anti-coagulation therapy' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography